Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.
Attenuated strains of Sabin poliovirus vaccine replicate in the human gut and, in rare cases, may cause vaccine-associated paralytic poliomyelitis (VAPP). The genetic instability of Sabin strains constitutes one of the main causes of VAPP, a disease that is most frequently associated with type 3 and type 2 Sabin strains, and more rarely with type 1 Sabin strains. In the present study, the growth phenotype of eight oral poliovirus vaccine (OPV) isolates (two non-recombinants and six recombinants), as well as of Sabin vaccine strains, was evaluated using two different assays, the reproductive capacity at different temperatures (Rct) test and the one-step growth curve test in Hep-2 cells at two different temperatures (37°C and 40°C). The growth phenotype of isolates was correlated with genomic modifications in order to identify the determinants and mechanisms of reversion towards neurovirulence. All of the recombinant OPV isolates showed a thermoresistant phenotype in the Rct test. Moreover, both recombinant Sabin-3 isolates showed significantly higher viral yield than Sabin 3 vaccine strain at 37°C and 40°C in the one-step growth curve test. All of the OPV isolates displayed mutations at specific sites of the viral genome, which are associated with the attenuated and temperature-sensitive phenotype of Sabin strains. The results showed that both mutations and recombination events could affect the phenotype traits of Sabin derivatives and may lead to the reversion of vaccinal strains to neurovirulent ones. The use of phenotypic markers along with the genomic analysis may shed additional light on the molecular determinants of the reversed neurovirulent phenotype of Sabin derivatives.
Pliaka
V
V
Department of Biochemistry and Biotechnology, Microbiology-Virology Laboratory, University of Thessaly, School of Health Sciences, Ploutonos 26 and Aiolou Str., 41221 Larissa, Greece.
Kyriakopoulou
Z
Z
Tsakogiannis
D
D
Ruether
I G A
IG
Gartzonika
C
C
Levidiotou-Stefanou
S
S
Krikelis
A
A
Markoulatos
P
P
D002460:Cell Line; D016679:Genome, Viral; D006801:Humans; D007700:Kinetics; D009154:Mutation; D017955:Poliovirus / Q000235:genetics / Q000254:growth & development* / Q000302:isolation & purification / Q000472:pathogenicity*; D011055:Poliovirus Vaccine, Oral; D012367:RNA, Viral / Q000235:genetics; D011995:Recombination, Genetic; D017422:Sequence Analysis, DNA; D013696:Temperature; D014613:Vaccines, Attenuated
D011055:Poliovirus Vaccine, Oral; D012367:RNA, Viral; D014613:Vaccines, Attenuated
J Virol. 1989 May;63(5):2357-60
2539524
Dev Biol Stand. 1993;78:93-9; discussion 99-100
8388835
J Virol. 1995 Sep;69(9):5278-86
7636970
J Gen Virol. 2009 Aug;90(Pt 8):1859-1868
19403755
Virology. 1993 Sep;196(1):199-208
8102826
Virology. 1994 Jul;202(1):370-8
8009849
Annu Rev Genet. 1993;27:353-436
8122908
Eur J Epidemiol. 1995 Dec;11(6):647-54
8861848
J Virol. 2002 Nov;76(21):10921-8
12368335
Virology. 1991 Dec;185(2):934-7
1660210
Prog Med Virol. 1978;24:178-206
212784
J Virol. 1987 Sep;61(9):2917-20
3039178
J Virol. 1995 Aug;69(8):4972-8
7609067
J Virol. 2002 Nov;76(21):10617-26
12368304
J Med Virol. 2008 Feb;80(2):352-9
18098139
J Virol. 1990 Oct;64(10):4922-9
2168976
J Virol. 2004 Dec;78(24):13839-47
15564492
J Virol. 1990 May;64(5):1934-45
2157861
Mol Cell Probes. 2007 Aug;21(4):267-75
17336496
J Gen Virol. 1986 Jul;67 ( Pt 7):1283-91
2425046
J Virol. 2005 Jan;79(2):1062-70
15613335
J Clin Microbiol. 2007 Aug;45(8):2419-25
17581940
J Virol. 2005 Nov;79(22):14235-43
16254358
Virology. 1991 Oct;184(2):645-54
1679577
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):79-84
10618374
J Gen Virol. 1999 Apr;80 ( Pt 4):907-916
10211959
J Virol. 1992 May;66(5):3194-7
1313923
J Virol. 2001 Jul;75(13):5740-51
11390576
Mol Cell Biol. 1988 Mar;8(3):1103-12
2835660
Braz J Med Biol Res. 1995 Jul;28(7):733-42
8580863
J Virol. 2004 Oct;78(20):11097-107
15452230
Acta Virol. 1996 Jun;40(3):157-70
8891097
Virology. 1991 Feb;180(2):648-58
1846492
J Mol Biol. 1989 May 20;207(2):379-92
2547075
J Virol. 1989 Mar;63(3):1302-9
2536835
Virus Res. 1991 Oct;21(2):111-22
1661980
Virology. 1989 Oct;172(2):408-14
2552655
Virus Genes. 2007 Dec;35(3):541-8
17680217
Clin Infect Dis. 1992 Feb;14(2):568-79
1554844
Virology. 1989 Feb;168(2):201-9
2536978
J Virol. 2009 Apr;83(7):3402-6
19129444
Mol Cell Probes. 2004 Apr;18(2):103-9
15051119
Dev Biol Stand. 1993;78:33-8
8099049
Virus Genes. 2010 Apr;40(2):200-11
20091423
Virus Genes. 2006 Apr;32(2):203-10
16604453
Virology. 1991 Apr;181(2):451-8
1707566
Nature. 1985 Apr 11-17;314(6011):548-50
2986004
J Infect Dis. 1991 Jul;164(1):191-4
1647422
J Virol. 1986 May;58(2):348-58
3009852
J Virol. 2002 Jul;76(13):6791-9
12050392
J Virol. 2000 Aug;74(16):7381-90
10906191
J Biol Chem. 2004 Mar 12;279(11):10261-9
14672927
J Virol. 1995 Dec;69(12):7601-5
7494267
Virus Genes. 2006 Oct;33(2):183-91
16972033
Am J Epidemiol. 1994 Dec 15;140(12):1111-24
7998593
Biologicals. 1993 Dec;21(4):357-63
8024751
J Med Virol. 2002 Nov;68(3):445-51
12226835
J Virol. 2000 Nov;74(22):10359-70
11044080
Vaccine. 1994 May;12(6):503-7
8036823
Virology. 1995 Dec 20;214(2):559-70
8553558
J Virol. 1997 Oct;71(10):7758-68
9311861
J Virol. 1993 Aug;67(8):4630-8
8392604
J Virol. 1991 May;65(5):2707-10
1850043
J Gen Virol. 1989 May;70 ( Pt 5):1117-23
2543771
J Gen Virol. 2003 Mar;84(Pt 3):573-580
12604808
J Virol. 1989 Mar;63(3):1338-44
2536836
Virology. 1993 Jan;192(1):18-26
8390752
J Virol. 1994 Dec;68(12):8089-101
7966599
J Infect Dis. 2004 Jul 15;190(2):409-16
15216480
J Virol. 2000 Nov;74(22):10371-80
11044081
J Clin Microbiol. 2000 Dec;38(12):4337-42
11101561
MMWR Recomm Rep. 1997 Jan 24;46(RR-3):1-25
9026708
J Virol. 1997 May;71(5):3826-33
9094658
Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):199-203
1846038